Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.
Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.